Angioedema Treatment Market by Drug Class (Bradykinin Receptor Antagonists, C1 Inhibitors, Kallikrein Inhibitors), Administration Route (Injectable, Oral), Disease Type, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Angioedema Treatment Market was valued at USD 5.50 billion in 2024 and is projected to grow to USD 6.47 billion in 2025, with a CAGR of 18.48%, reaching USD 21.36 billion by 2032.
A concise orientation to the clinical profile, evolving therapeutic options, and systemic care dynamics shaping angioedema treatment strategies and decision-making
Angioedema presents a complex clinical and commercial landscape shaped by episodic morbidity, evolving therapeutic modalities, and growing emphasis on patient-centered care. Clinicians and health systems are increasingly balancing acute management with long-term prophylaxis, which has elevated attention on both novel molecular targets and practical considerations such as route of administration, adherence, and care settings. Recent advances in biological agents and small molecule inhibitors have expanded clinical pathways, while regulatory approvals, payer policies, and real-world evidence are reshaping treatment algorithms.
As stakeholders navigate this environment, they must reconcile clinical efficacy with delivery feasibility and access. The interplay between injectable biologics and emergent oral therapies influences patient preference, adherence patterns, and provider workflows. Concurrently, outpatient and home-care models are maturing, creating opportunities for care decentralization but also raising issues around training, storage, and emergency readiness. This introduction frames the disease context, therapeutic developments, and system-level dynamics that inform strategic decisions for manufacturers, providers, and payers.
How scientific breakthroughs, decentralization of care, and payer expectations are collectively redefining therapeutic positioning and patient management across angioedema care pathways
The angioedema landscape is experiencing transformative shifts driven by scientific innovation, care model evolution, and intensified attention to patient experience. Mechanistic advances have prioritized pathway-specific interventions that interrupt bradykinin signaling and kallikrein activity, enabling more targeted and tolerable prophylactic strategies. These innovations are accompanied by decentralized care trends: home infusion programs, patient self-administration training, and telehealth-enabled monitoring have reduced the reliance on acute care visits while empowering patients with greater control over flare management.
Concurrently, payer frameworks and contracting approaches are transitioning toward value-based arrangements that reward demonstrable reductions in emergency utilization and hospital admissions. Clinical trial designs now emphasize patient-reported outcomes and health resource utilization metrics to support these payer demands. Supply chain resilience and manufacturing agility have become strategic priorities as companies pursue flexible production for both biologics and small molecules. Taken together, these shifts are redefining competitive differentiation: success increasingly requires integrated clinical evidence, adaptable delivery models, and robust patient support ecosystems.
Assessing how cumulative tariff measures enacted in 2025 are reshaping supply chains, procurement strategies, and commercial planning for angioedema therapies
The implementation of cumulative United States tariffs in 2025 has introduced new considerations across sourcing, manufacturing, and pricing strategies for angioedema therapies. Procurement teams are recalibrating supplier relationships to mitigate input cost volatility, particularly for components and intermediates sourced internationally. Manufacturers with vertically integrated or geographically diversified production footprints have a relative advantage in softening immediate cost impacts and sustaining supply continuity. In contrast, entities reliant on single-region manufacturing or specialized CDMOs may encounter extended lead times and higher landed costs.
These dynamics prompt a range of strategic responses. Firms are accelerating nearshoring and dual-sourcing initiatives to reduce exposure to tariff-induced downstream cost pressure. Commercial teams are reassessing contracting clauses with distributors and payers to preserve channel economics without shifting disproportionate burden to patients. Additionally, regulatory and quality assurance functions are prioritizing faster qualification of alternative suppliers to maintain uninterrupted access. Overall, the tariff environment is amplifying the importance of supply chain transparency, contractual flexibility, and scenario planning for therapeutic programs across the development and commercialization continuum.
Strategic segmentation analysis revealing how drug class, administration route, disease type, care setting, and distribution channels determine adoption and positioning
Segmentation provides a structured way to interpret demand drivers, clinical pathways, and channel dynamics across the angioedema ecosystem. Based on drug class, treatments are differentiated among Bradykinin Receptor Antagonists, C1 Inhibitors, and Kallikrein Inhibitors, each presenting unique efficacy profiles, safety considerations, and administration challenges that influence positioning and adoption in prophylaxis versus acute care. Differences in mechanism of action also affect clinical trial endpoints and comparative effectiveness assessments, which are critical to value messaging and formulary negotiations.
Based on administration route, injectable and oral options create divergent patient journeys: injectables often require clinical training or supervised administration and align with high-efficacy biologic profiles, while oral therapies promise convenience and adherence advantages that can reshape prescribing patterns. Based on disease type, the clinical management of Acquired, Hereditary, and Idiopathic angioedema varies substantially, with hereditary forms typically demanding long-term prophylaxis and coordinated specialty care, whereas acquired and idiopathic presentations may necessitate tailored diagnostic workups and episodic treatment strategies. Based on end user, Home Care, Hospitals, and Specialty Clinics each impose distinct operational constraints and revenue models, affecting adoption of self-administered products versus facility-delivered therapies. Based on distribution channel, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways influence dispensing logistics, reimbursement interactions, and patient convenience, and they require differentiated commercial approaches to secure placement and adherence support. Synthesizing these segmentation lenses clarifies where investment in clinical data, patient support, and supply chain capabilities will deliver the most strategic return.
Regional dynamics and access complexities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory, reimbursement, and distribution strategies
Regional dynamics exert substantial influence on regulatory pathways, payer behavior, and care delivery models, shaping how therapies for angioedema are developed and brought to patients. In the Americas, regulatory agencies and integrated payer systems place heavy emphasis on outcomes and cost offsets, while decentralized healthcare delivery fosters the rapid adoption of home-administered options and specialty pharmacy support. This region also demonstrates strong clinical trial activity and patient advocacy engagement, which accelerates real-world evidence generation and awareness campaigns.
Europe, Middle East & Africa present a heterogeneous landscape where centralized regulatory pathways coexist with country-level reimbursement variability; pricing and access negotiations are often protracted and linked to health technology assessment outcomes. In this region, established hospital networks and specialty clinics remain pivotal for initiating complex therapies, and manufacturer strategies must account for diverse tendering practices and procurement timelines. Asia-Pacific is characterized by rapid uptake of innovative therapies in certain markets alongside constrained access in others, driving manufacturers to pursue tiered pricing strategies, local partnerships, and technology transfer arrangements. Across all regions, manufacturers that combine robust clinical evidence, flexible distribution partnerships, and localized patient support offerings are best positioned to navigate regulatory complexity and accelerate adoption.
How incumbent biologics manufacturers, nimble biotech innovators, and collaborative partnerships are shaping competitive positioning in angioedema treatment
Competitive dynamics in angioedema treatment are shaped by a mix of established biologics developers, specialized biotech innovators, and emerging clinical-stage programs focused on novel targets. Leading organizations are leveraging deep clinical portfolios, large-scale manufacturing capabilities, and established payer relationships to defend position in prophylactic and on-demand segments. At the same time, smaller and mid-sized companies are differentiating through mechanism-specific molecules, patient-centric delivery formats, and nimble evidence-generation strategies that emphasize quality-of-life outcomes and reduction in emergency utilization.
Partnerships and licensing deals are common strategic plays to accelerate access to complementary assets or to expand commercial reach into new geographies. There is a marked emphasis on building integrated patient support services-ranging from training for self-administration to digital adherence tools-that enhance persistence and strengthen value propositions to payers. Manufacturing scale-up and biologics know-how remain critical barriers to entry for complex protein therapeutics, whereas well-resourced entrants can rapidly alter competitive dynamics by demonstrating comparable effectiveness with improved administration or cost profiles. Overall, companies that align clinical differentiation with operational excellence and payer-aligned evidence will gain durable advantage.
Actionable strategic playbook for leaders to align clinical innovation, supply resilience, payer engagement, and patient support for competitive differentiation
Industry leaders should prioritize a coordinated strategy that aligns R&D, commercial, and operational functions to capture both clinical and access value. First, invest in diversified delivery formats and patient-centered design so that pipeline projects consider oral and self-administered pathways early in development to broaden adoption and reduce care friction. Second, build resilient supply chains through dual sourcing and selective nearshoring to lower exposure to trade disruptions and tariff-related cost pressures while maintaining quality assurance standards.
Third, engage payers early with robust real-world evidence and outcomes studies that emphasize reductions in emergency utilization and improvements in productivity and quality of life. Fourth, develop comprehensive patient support ecosystems combining education, training, and digital adherence tools to improve persistence and reduce acute events. Fifth, pursue strategic alliances with specialty pharmacies, home-care providers, and regional distributors to optimize channel access. Finally, embed flexible contracting approaches-such as outcome-based arrangements or risk-sharing pilots-into commercial models to align incentives with clinical impact and payer priorities.
A rigorous multi-method research approach combining clinical literature review, expert interviews, real-world datasets, and supply chain analysis to underpin strategic conclusions
The research underpinning this analysis draws on a multi-method approach to ensure robust conclusions and pragmatic guidance. The foundation comprises systematic reviews of peer-reviewed clinical literature, regulatory filings, clinical trial registries, and treatment guidelines to characterize mechanistic innovation, efficacy signals, and safety profiles. Primary research includes structured interviews with clinicians, specialty pharmacists, and payer representatives to capture real-world prescribing behavior, access barriers, and reimbursement considerations. Patient registries and observational datasets were consulted to understand care pathways, utilization patterns, and patient-reported outcomes.
Qualitative insights were triangulated with supply chain and commercial intelligence gathered from industry disclosures, public procurement records, and drug master file trends to assess manufacturing and distribution implications. Findings were validated through expert panels and scenario testing to identify vulnerabilities and strategic levers. Limitations include variability in regional data granularity and evolving clinical evidence, both of which were addressed by iterative expert validation and sensitivity checks to preserve confidence in strategic recommendations.
Concise synthesis of strategic imperatives emphasizing clinical differentiation, access alignment, and operational resilience to drive improved patient outcomes
In summary, the angioedema treatment landscape is at an inflection point where mechanistic innovation, delivery format evolution, and changing care models converge to create new opportunities and operational challenges. Strategic differentiation will depend on the ability to translate mechanistic advantages into tangible patient and payer outcomes while ensuring that manufacturing and distribution systems are resilient against trade and supply-chain disruptions. Stakeholders that align clinical development with pragmatic access strategies-emphasizing patient convenience, evidence of reduced acute resource use, and flexible contracting-will be best positioned to realize sustainable value.
Looking ahead, continued investment in patient-reported outcomes, decentralized care infrastructure, and collaborative evidence-generation will be essential. Executives should anticipate iterative shifts in payer expectations and prepare to demonstrate both clinical benefit and system-level savings. By adopting integrated approaches that combine therapeutic innovation, commercial agility, and operational robustness, organizations can navigate the complex environment and deliver meaningful improvements in care for patients living with hereditary, acquired, and idiopathic angioedema.
Please Note: PDF & Excel + Online Access - 1 Year
A concise orientation to the clinical profile, evolving therapeutic options, and systemic care dynamics shaping angioedema treatment strategies and decision-making
Angioedema presents a complex clinical and commercial landscape shaped by episodic morbidity, evolving therapeutic modalities, and growing emphasis on patient-centered care. Clinicians and health systems are increasingly balancing acute management with long-term prophylaxis, which has elevated attention on both novel molecular targets and practical considerations such as route of administration, adherence, and care settings. Recent advances in biological agents and small molecule inhibitors have expanded clinical pathways, while regulatory approvals, payer policies, and real-world evidence are reshaping treatment algorithms.
As stakeholders navigate this environment, they must reconcile clinical efficacy with delivery feasibility and access. The interplay between injectable biologics and emergent oral therapies influences patient preference, adherence patterns, and provider workflows. Concurrently, outpatient and home-care models are maturing, creating opportunities for care decentralization but also raising issues around training, storage, and emergency readiness. This introduction frames the disease context, therapeutic developments, and system-level dynamics that inform strategic decisions for manufacturers, providers, and payers.
How scientific breakthroughs, decentralization of care, and payer expectations are collectively redefining therapeutic positioning and patient management across angioedema care pathways
The angioedema landscape is experiencing transformative shifts driven by scientific innovation, care model evolution, and intensified attention to patient experience. Mechanistic advances have prioritized pathway-specific interventions that interrupt bradykinin signaling and kallikrein activity, enabling more targeted and tolerable prophylactic strategies. These innovations are accompanied by decentralized care trends: home infusion programs, patient self-administration training, and telehealth-enabled monitoring have reduced the reliance on acute care visits while empowering patients with greater control over flare management.
Concurrently, payer frameworks and contracting approaches are transitioning toward value-based arrangements that reward demonstrable reductions in emergency utilization and hospital admissions. Clinical trial designs now emphasize patient-reported outcomes and health resource utilization metrics to support these payer demands. Supply chain resilience and manufacturing agility have become strategic priorities as companies pursue flexible production for both biologics and small molecules. Taken together, these shifts are redefining competitive differentiation: success increasingly requires integrated clinical evidence, adaptable delivery models, and robust patient support ecosystems.
Assessing how cumulative tariff measures enacted in 2025 are reshaping supply chains, procurement strategies, and commercial planning for angioedema therapies
The implementation of cumulative United States tariffs in 2025 has introduced new considerations across sourcing, manufacturing, and pricing strategies for angioedema therapies. Procurement teams are recalibrating supplier relationships to mitigate input cost volatility, particularly for components and intermediates sourced internationally. Manufacturers with vertically integrated or geographically diversified production footprints have a relative advantage in softening immediate cost impacts and sustaining supply continuity. In contrast, entities reliant on single-region manufacturing or specialized CDMOs may encounter extended lead times and higher landed costs.
These dynamics prompt a range of strategic responses. Firms are accelerating nearshoring and dual-sourcing initiatives to reduce exposure to tariff-induced downstream cost pressure. Commercial teams are reassessing contracting clauses with distributors and payers to preserve channel economics without shifting disproportionate burden to patients. Additionally, regulatory and quality assurance functions are prioritizing faster qualification of alternative suppliers to maintain uninterrupted access. Overall, the tariff environment is amplifying the importance of supply chain transparency, contractual flexibility, and scenario planning for therapeutic programs across the development and commercialization continuum.
Strategic segmentation analysis revealing how drug class, administration route, disease type, care setting, and distribution channels determine adoption and positioning
Segmentation provides a structured way to interpret demand drivers, clinical pathways, and channel dynamics across the angioedema ecosystem. Based on drug class, treatments are differentiated among Bradykinin Receptor Antagonists, C1 Inhibitors, and Kallikrein Inhibitors, each presenting unique efficacy profiles, safety considerations, and administration challenges that influence positioning and adoption in prophylaxis versus acute care. Differences in mechanism of action also affect clinical trial endpoints and comparative effectiveness assessments, which are critical to value messaging and formulary negotiations.
Based on administration route, injectable and oral options create divergent patient journeys: injectables often require clinical training or supervised administration and align with high-efficacy biologic profiles, while oral therapies promise convenience and adherence advantages that can reshape prescribing patterns. Based on disease type, the clinical management of Acquired, Hereditary, and Idiopathic angioedema varies substantially, with hereditary forms typically demanding long-term prophylaxis and coordinated specialty care, whereas acquired and idiopathic presentations may necessitate tailored diagnostic workups and episodic treatment strategies. Based on end user, Home Care, Hospitals, and Specialty Clinics each impose distinct operational constraints and revenue models, affecting adoption of self-administered products versus facility-delivered therapies. Based on distribution channel, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways influence dispensing logistics, reimbursement interactions, and patient convenience, and they require differentiated commercial approaches to secure placement and adherence support. Synthesizing these segmentation lenses clarifies where investment in clinical data, patient support, and supply chain capabilities will deliver the most strategic return.
Regional dynamics and access complexities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory, reimbursement, and distribution strategies
Regional dynamics exert substantial influence on regulatory pathways, payer behavior, and care delivery models, shaping how therapies for angioedema are developed and brought to patients. In the Americas, regulatory agencies and integrated payer systems place heavy emphasis on outcomes and cost offsets, while decentralized healthcare delivery fosters the rapid adoption of home-administered options and specialty pharmacy support. This region also demonstrates strong clinical trial activity and patient advocacy engagement, which accelerates real-world evidence generation and awareness campaigns.
Europe, Middle East & Africa present a heterogeneous landscape where centralized regulatory pathways coexist with country-level reimbursement variability; pricing and access negotiations are often protracted and linked to health technology assessment outcomes. In this region, established hospital networks and specialty clinics remain pivotal for initiating complex therapies, and manufacturer strategies must account for diverse tendering practices and procurement timelines. Asia-Pacific is characterized by rapid uptake of innovative therapies in certain markets alongside constrained access in others, driving manufacturers to pursue tiered pricing strategies, local partnerships, and technology transfer arrangements. Across all regions, manufacturers that combine robust clinical evidence, flexible distribution partnerships, and localized patient support offerings are best positioned to navigate regulatory complexity and accelerate adoption.
How incumbent biologics manufacturers, nimble biotech innovators, and collaborative partnerships are shaping competitive positioning in angioedema treatment
Competitive dynamics in angioedema treatment are shaped by a mix of established biologics developers, specialized biotech innovators, and emerging clinical-stage programs focused on novel targets. Leading organizations are leveraging deep clinical portfolios, large-scale manufacturing capabilities, and established payer relationships to defend position in prophylactic and on-demand segments. At the same time, smaller and mid-sized companies are differentiating through mechanism-specific molecules, patient-centric delivery formats, and nimble evidence-generation strategies that emphasize quality-of-life outcomes and reduction in emergency utilization.
Partnerships and licensing deals are common strategic plays to accelerate access to complementary assets or to expand commercial reach into new geographies. There is a marked emphasis on building integrated patient support services-ranging from training for self-administration to digital adherence tools-that enhance persistence and strengthen value propositions to payers. Manufacturing scale-up and biologics know-how remain critical barriers to entry for complex protein therapeutics, whereas well-resourced entrants can rapidly alter competitive dynamics by demonstrating comparable effectiveness with improved administration or cost profiles. Overall, companies that align clinical differentiation with operational excellence and payer-aligned evidence will gain durable advantage.
Actionable strategic playbook for leaders to align clinical innovation, supply resilience, payer engagement, and patient support for competitive differentiation
Industry leaders should prioritize a coordinated strategy that aligns R&D, commercial, and operational functions to capture both clinical and access value. First, invest in diversified delivery formats and patient-centered design so that pipeline projects consider oral and self-administered pathways early in development to broaden adoption and reduce care friction. Second, build resilient supply chains through dual sourcing and selective nearshoring to lower exposure to trade disruptions and tariff-related cost pressures while maintaining quality assurance standards.
Third, engage payers early with robust real-world evidence and outcomes studies that emphasize reductions in emergency utilization and improvements in productivity and quality of life. Fourth, develop comprehensive patient support ecosystems combining education, training, and digital adherence tools to improve persistence and reduce acute events. Fifth, pursue strategic alliances with specialty pharmacies, home-care providers, and regional distributors to optimize channel access. Finally, embed flexible contracting approaches-such as outcome-based arrangements or risk-sharing pilots-into commercial models to align incentives with clinical impact and payer priorities.
A rigorous multi-method research approach combining clinical literature review, expert interviews, real-world datasets, and supply chain analysis to underpin strategic conclusions
The research underpinning this analysis draws on a multi-method approach to ensure robust conclusions and pragmatic guidance. The foundation comprises systematic reviews of peer-reviewed clinical literature, regulatory filings, clinical trial registries, and treatment guidelines to characterize mechanistic innovation, efficacy signals, and safety profiles. Primary research includes structured interviews with clinicians, specialty pharmacists, and payer representatives to capture real-world prescribing behavior, access barriers, and reimbursement considerations. Patient registries and observational datasets were consulted to understand care pathways, utilization patterns, and patient-reported outcomes.
Qualitative insights were triangulated with supply chain and commercial intelligence gathered from industry disclosures, public procurement records, and drug master file trends to assess manufacturing and distribution implications. Findings were validated through expert panels and scenario testing to identify vulnerabilities and strategic levers. Limitations include variability in regional data granularity and evolving clinical evidence, both of which were addressed by iterative expert validation and sensitivity checks to preserve confidence in strategic recommendations.
Concise synthesis of strategic imperatives emphasizing clinical differentiation, access alignment, and operational resilience to drive improved patient outcomes
In summary, the angioedema treatment landscape is at an inflection point where mechanistic innovation, delivery format evolution, and changing care models converge to create new opportunities and operational challenges. Strategic differentiation will depend on the ability to translate mechanistic advantages into tangible patient and payer outcomes while ensuring that manufacturing and distribution systems are resilient against trade and supply-chain disruptions. Stakeholders that align clinical development with pragmatic access strategies-emphasizing patient convenience, evidence of reduced acute resource use, and flexible contracting-will be best positioned to realize sustainable value.
Looking ahead, continued investment in patient-reported outcomes, decentralized care infrastructure, and collaborative evidence-generation will be essential. Executives should anticipate iterative shifts in payer expectations and prepare to demonstrate both clinical benefit and system-level savings. By adopting integrated approaches that combine therapeutic innovation, commercial agility, and operational robustness, organizations can navigate the complex environment and deliver meaningful improvements in care for patients living with hereditary, acquired, and idiopathic angioedema.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption rates of self-administered subcutaneous C1 inhibitor therapies among hereditary angioedema patients in North America
- 5.2. Cost impact analysis of emerging gene therapies targeting factor XII for recurrent angioedema management in Europe
- 5.3. Patient preference shift towards on-demand kallikrein inhibitors over prophylactic C1 esterase replacement therapies
- 5.4. Regulatory pathways and reimbursement challenges delaying market access of pediatric-friendly icatibant biosimilars
- 5.5. Use of real-world evidence from electronic health records to identify angioedema treatment adherence patterns in Asian markets
- 5.6. Development of orally bioavailable bradykinin B2 receptor antagonists to improve chronic angioedema disease control
- 5.7. Integration of telemedicine platforms to monitor treatment outcomes in hereditary and acquired angioedema patients
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Angioedema Treatment Market, by Drug Class
- 8.1. Bradykinin Receptor Antagonists
- 8.2. C1 Inhibitors
- 8.3. Kallikrein Inhibitors
- 9. Angioedema Treatment Market, by Administration Route
- 9.1. Injectable
- 9.2. Oral
- 10. Angioedema Treatment Market, by Disease Type
- 10.1. Acquired
- 10.2. Hereditary
- 10.3. Idiopathic
- 11. Angioedema Treatment Market, by End User
- 11.1. Home Care
- 11.2. Hospitals
- 11.3. Specialty Clinics
- 12. Angioedema Treatment Market, by Distribution Channel
- 12.1. Hospital Pharmacy
- 12.2. Online Pharmacy
- 12.3. Retail Pharmacy
- 13. Angioedema Treatment Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Angioedema Treatment Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Angioedema Treatment Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Takeda Pharmaceutical Company Limited
- 16.3.2. CSL Behring
- 16.3.3. Pharming Group N.V.
- 16.3.4. BioCryst Pharmaceuticals, Inc.
- 16.3.5. Sanofi S.A.
- 16.3.6. Ionis Pharmaceuticals, Inc.
- 16.3.7. KalVista Pharmaceuticals Ltd.
- 16.3.8. Otsuka Pharmaceutical Co., Ltd.
- 16.3.9. Teva Pharmaceutical Industries Ltd.
- 16.3.10. Pfizer Inc.
- 16.3.11. Novartis AG
- 16.3.12. Merck & Co., Inc.
- 16.3.13. Bayer AG
- 16.3.14. GlaxoSmithKline plc
- 16.3.15. AstraZeneca plc
- 16.3.16. Attune Pharmaceuticals, Inc.
- 16.3.17. Adverum Biotechnologies, Inc.
- 16.3.18. Intellia Therapeutics, Inc.
- 16.3.19. Argenx NV
- 16.3.20. Sobi
- 16.3.21. HAE Pharma LLC
- 16.3.22. Pharvaris Netherlands B.V.
- 16.3.23. Aurobindo Pharma Ltd.
- 16.3.24. Cipla Limited
- 16.3.25. Dr. Reddy’s Laboratories Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
